Daily treatment with AZP-3601, Amolyt Pharma’s experimental therapy for hypoparathyroidism, safely and effectively normalizes calcium levels in people…
Articles by Patricia Inácio, PhD
The HypoPARAthyroidism Association has launched the first-of-its-kind Patient-Powered Data Platform, a repository to help understand the disease journey…
Daily treatment with AZP-3601, Amolyt Pharma’s investigational therapy for hypoparathyroidism, was well tolerated and allowed patients to discontinue standard…
Six months of treatment with Forteo (teriparatide) — a lab-made parathyroid hormone fragment approved for osteoporosis — safely led to…
Impaired activity of the adrenal glands, a condition called Addison’s disease, may be the only typical manifestation of autoimmune polyglandular…
Children with thyroid cancer or disease who undergo surgery to remove that gland can commonly have their parathyroid glands accidentally…
Amolyt Pharma has raised $80 million in financing that will support the clinical development of AZP-3601, its experimental…
Ahead of this year’s Rare Disease Week on Capitol Hill, held virtually July 14–22, the EveryLife Foundation will…
More than half of the people with rare diseases and their caregivers, asked in a survey, were undecided or less…
The EveryLife Foundation for Rare Diseases is accepting applications for a scholarship program that aims to help adults with a…